Alerta

TUMOR NEOANTIGEN VACCINE SYSTEM SPECIFICALLY MARKING HETEROLOGOUS PROTEIN, AND USE THEREOF

Absstract of: WO2025081515A1

The present invention provides a tumor neoantigen vaccine system specifically marking a heterologous protein, and a use thereof. The vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus; the heterologous protein mRNA vaccine is used to induce an organism to generate heterologous protein-specific memory T cells, and the recombinant oncolytic virus is used to promote a tumor to express microorganism-derived tumor neoantigens. When pre-immunized memory T cells detect these marked specific neoantigens, the tumor expressing the neoantigens is quickly activated and killed, the release of tumor autoantigens is promoted, dendritic cells phagocytize antigens to further initiate an anti-tumor response, and a systemic anti-tumor immune effect is activated by means of antigenic epitope spreading.

METHOD FOR PREPARING BIOFLOC CULTURE MEDIUM BY USING ORGANIC WASTES

Absstract of: WO2025081938A1

Provided is a method for preparing a biofloc culture medium by using organic wastes. The method comprises: adding a first auxiliary material to organic wastes, uniformly mixing same to obtain a mixture, and adjusting the water content of the mixture to 45-55%; inoculating an activated Bacillus subtilis seed culture, Bacillus licheniformis seed culture and Saccharomyces cerevisiae seed culture into the mixture according to a ratio, and performing fermentation with stirring and ventilation, so as to obtain a fermented product; adding a second auxiliary material to the fermented product, and uniformly mixing same to obtain the biofloc culture medium. In the finished biofloc product prepared by the method, the viable count of Bacillus subtilis is greater than or equal to 400 million cfu/g, the viable count of Bacillus licheniformis is greater than or equal to 200 million cfu/g, the viable count of Saccharomyces cerevisiae is greater than or equal to 1200 million cfu/g, the total number of bacterial colonies is greater than or equal to 8000 million cfu/g, and no salmonella is detected. The present application can solve the pollution problem of livestock and poultry manure and further achieves recycling utilization of livestock and poultry manure.

標的微生物を検出するための反応媒体、及び関連する方法

Absstract of: AU2023262222A1

The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a sample that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.

Immunochromatography test strip for detecting shiga toxin-producing escherichia coli O103

Absstract of: CN119846199A

The invention relates to the technical field of analysis and detection, in particular to an immunochromatography test strip for detecting shiga toxin-producing escherichia coli O103. Based on the characteristics of the quantum dots and the fluorescent microspheres, a probe is synthesized by utilizing the purified protein expressed by the pET-28a-O103 strain and the fluorescent microspheres, and the immunochromatography rapid detection test strip for identifying the shiga toxin-producing escherichia coli O103, which is simple to operate, is established, can be used for rapidly identifying the shiga toxin-producing escherichia coli O103 clinically, and can be used for rapidly detecting the shiga toxin-producing escherichia coli O103. The method has important significance on prevention and control of Escherichia coli diseases.

Lactobacillus rhamnosus and application thereof

Absstract of: CN119842544A

The invention belongs to the field of microorganisms, and relates to lactobacillus rhamnosus and application thereof. The lactobacillus rhamnosus KC3 is separated from Xinjiang healthy bactrian camel milk, and the lactobacillus rhamnosus KC3 has the activity of inhibiting various pathogenic bacteria such as escherichia coli, klebsiella pneumoniae, salmonella, proteus mirabilis, staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes and streptococcus agalactiae. The metabiotics of the strain can enhance the sensitivity of pathogenic bacteria such as escherichia coli and staphylococcus aureus to antibiotics such as beta-lactam antibiotics, and can synergistically enhance the antibacterial effect of the beta-lactam antibiotics to the pathogenic bacteria such as escherichia coli, staphylococcus aureus, CRE or MRSA. The lactobacillus rhamnosus KC3 metagen can also destroy cell walls of pathogenic bacteria such as escherichia coli, staphylococcus epidermidis, CRE or MRSA and the like, and the formation of bacterial biofilms is inhibited.

Methods of using symbiotic compositions to resist salmonella typhimurium infection

Absstract of: CN119855897A

The present invention provides a method for producing a recombinant bacterium, which is characterized in that the recombinant bacterium is used for producing a recombinant bacterium, and the recombinant bacterium is obtained by using a recombinant bacterium, which is preserved in the Deersche Sammlarg von Mikroorgani sung Zel lkulturen and has been preserved in the Deersche Sammlarg von Mikroorgani sung Zel lkulturen with a preservation number of DSM 32786. The present invention relates to a method for resisting Salmonella typhimurium infection by using a culture of Lactobacillus rhamnosus LRH10 having a preservation number of DSMZ GmbH, Lactobacillus paracasei LPC12 having a preservation number of DSMZ GmbH, Lactobacillus fermentum LF26 having a preservation number of DSMZ GmbH, Streptococcus thermophilus ST30 having a preservation number of DSMZ 32788, and Lactobacillus helveticus LH43 having a preservation number of DSMZ 32787, and more specifically, to a method for resisting Salmonella typhimurium infection by using a culture of Lactobacillus rhamnosus LRH10 having a preservation number of DSMZ GmbH.

鼠伤寒沙门菌毒力基因Ict的鉴定及其减毒疫苗候选株的制备与应用

Nº publicación: CN119842745A 18/04/2025

Applicant:

扬州大学

Absstract of: CN119842745A

本发明公开了鼠伤寒沙门菌毒力基因Ict的鉴定及其减毒疫苗候选株的制备与应用。本发明选择强毒力鼠伤寒沙门菌SL1344株作为亲本株，将其中降解代谢衣康酸的关键毒力基因Ict进行敲除，构建鼠伤寒沙门菌SL1344减毒疫苗候选株。通过小鼠动物毒力实验、免疫保护力实验和安全性实验等证实该疫苗候选株SL1344‑ΔIct缺失株，不仅对动物的致病力显著降低，且提供了良好的免疫原性和免疫保护力。本发明实现对强毒力鼠伤寒沙门氏菌株的减毒，可广泛应用于沙门菌的防控，为研制沙门菌的减毒活疫苗及活载体疫苗奠定基础。